ALYREF and urinary bladder carcinoma: Specifically, m5C-mediated ALYREF recognizes RABL6 and TK1 mRNA m5C modification through its K171 domain, enhancing mRNA splicing and stability to increase bladder cancer malignancy (Wang et al., 2023b).